Area of research
Hepatology · Epidemiology
Research interest
Research interests include Hepatitis C virus research, Liver Disease Diagnosis and Treatment, Hepatitis B Virus Studies, and Liver Disease and Transplantation.
Development and validation of the A-TANGO organ failure score for acute-on-chronic liver failure in global cohorts
Soluble urokinase plasminogen activator receptor is a prognostic biomarker in decompensated cirrhosis
Long-term outcomes after nucleos(t)ide analogue cessation in chronic hepatitis B – follow-up from the RETRACT-B cohort
Comparative evaluation of multimarker algorithms for early-stage HCC detection in multicenter prospective studies.
Exploring the effects of serum G-CSF levels in acute-on-chronic liver failure (ACLF): Insights from a post hoc analysis of the GRAFT study.
Dynamics of HBV biomarkers during nucleos(t)ide analog treatment: A 14-year study.
Soluble urokinase plasminogen activator receptor is a prognostic biomarker in decompensated cirrhosis
Pruritus in primary biliary cholangitis: insights from the German PBC registry across secondary and tertiary care
Impact of Handling Perception and Language Barriers on Virologic Response to Daily Subcutaneous Bulevirtide in Hepatitis D
Letter to the Editor: Clonal hematopoiesis in MASLD-associated HCC: Variant burden may matter more than presence.
Strong or Weak Consent in Medical Law? Identifying the Values Protected in Transplantation Medicine in Europe.
Comparison of CT-Guided Microwave Ablation of Liver Malignancies with and Without Intra-Arterial Catheter Placement for Contrast Administration.
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
A global action agenda for turning the tide on fatty liver disease.
S2k-Leitlinie Lebertransplantation der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV)
PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B.
Basal MET phosphorylation is an indicator of hepatocyte dysregulation in liver disease
Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD score.
Sub-optimal therapy of patients with primary biliary cholangitis (PBC) in the real-life stetting of the German PBC cohort
Successful hepatitis B and C screening in the health check-up in the German primary care setting.
Odevixibat treatment in an adult patient with advanced icteric progressive cholestatic liver disease.
Transitioning FIB-4 score: From fibrosis screening tool to key biomarker for clinical endpoints.
Clinical applications of circulating HBV RNA as a potential surrogate biomarker for intrahepatic cccDNA transcriptional activity.
Reply to: "A comment on `A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B'".
Prospective Analysis of Safety and Efficacy of Tenofovir Alafenamide Fumarate (TAF) in European Real-World Patients with Chronic Hepatitis B: A Single-Centre Real-Word Cohort Study.
Genetic Variation in Angiotensin II Type 1 Receptor Is Linked to Lipid Levels and Hepatic Steatosis in Alcohol-Associated Liver Disease, but Not to Cirrhosis or Hepatocellular Carcinoma
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
A global research priority agenda to advance public health responses to fatty liver disease
Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories
A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B